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Intake of food rich in saturated 
fat in relation to subclinical 
atherosclerosis and potential 
modulating effects from single 
genetic variants
Federica Laguzzi1*, Buamina Maitusong1,2, Rona J. Strawbridge3,4,5, Damiano Baldassarre6, 
Fabrizio Veglia7, Steve E. Humphries8, Rainer Rauramaa9,10, Sudhir Kurl11, Andries J. Smit12, 
Philippe Giral13, Angela Silveira14, Elena Tremoli7, Anders Hamsten14, Ulf de Faire1, 
Bruna Gigante4, Karin Leander1 & IMPROVE Study group* 
The relationship between intake of saturated fats and subclinical atherosclerosis, as well as the 
possible influence of genetic variants, is poorly understood and investigated. We aimed to investigate 
this relationship, with a hypothesis that it would be positive, and to explore whether genetics may 
modulate it, using data from a European cohort including 3,407 participants aged 54–79 at high risk 
of cardiovascular disease. Subclinical atherosclerosis was assessed by carotid intima-media thickness 
(C-IMT), measured at baseline and after 30 months. Logistic regression (OR; 95% CI) was employed to 
assess the association between high intake of food rich in saturated fat (vs. low) and: (1) the mean and 
the maximum values of C-IMT in the whole carotid artery (C-IMTmean, C-IMTmax), in the bifurcation (Bif-
), the common (CC-) and internal (ICA-) carotid arteries at baseline (binary, cut-point ≥ 75th), and (2) 
C-IMT progression (binary, cut-point > zero). For the genetic-diet interaction analyses, we considered 
100,350 genetic variants. We defined interaction as departure from additivity of effects. After age- and 
sex-adjustment, high intake of saturated fat was associated with increased C-IMTmean (OR:1.27;1.06–
1.47), CC-IMTmean (OR:1.22;1.04–1.44) and ICA-IMTmean (OR:1.26;1.07–1.48). However, in multivariate 
analysis results were no longer significant. No clear associations were observed between high 
intake of saturated fat and risk of atherosclerotic progression. There was no evidence of interactions 
between high intake of saturated fat and any of the genetic variants considered, after multiple 
testing corrections. High intake of saturated fats was not independently associated with subclinical 
atherosclerosis. Moreover, we did not identify any significant genetic-dietary fat interactions in 
relation to risk of subclinical atherosclerosis.
OPEN
1Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 
Nobels väg 13, Box 210, 17177 Stockholm, Sweden. 2Department of Cardiology, First Affiliated Hospital of Xinjiang 
Medical University, Urumqi, People’s Republic of China. 3Institute of Mental Health and Wellbeing, Mental Health 
and Wellbeing, University of Glasgow, Glasgow, UK. 4Cardiovascular Medicine Unit, Department of Medicine Solna, 
Karolinska Institutet, Stockholm, Sweden. 5Health Data Research United Kingdom, London, UK. 6Department 
of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milan, Italy. 7Centro 
Cardiologico Monzino, IRCCS, Milan, Italy. 8Centre for Cardiovascular Genetics, Institute Cardiovascular Science, 
University College London, London, UK. 9Foundation for Research in Health Exercise and Nutrition, Kuopio 
Research Institute of Exercise Medicine, Kuopio, Finland. 10Department of Clinical Physiology and Nuclear 
Medicine, Kuopio University Hospital, Kuopio, Finland. 11Institute of Public Health and Clinical Nutrition, University 
of Eastern Finland, Kuopio, Finland. 12Department of Medicine, University Medical Center Groningen, Groningen, 
The Netherlands. 13Assistance Publique-Hôpitaux de Paris, Service Endocrinologie-Métabolisme, Groupe 
Hospitalier Pitié-Salpétrière, Unités de Prévention Cardiovasculaire, Paris, France. 14Cardiovascular Medicine 
Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden.  *A list of 
authors and their affiliations appears at the end of the paper. *email: federica.laguzzi@ki.se
2
Vol:.(1234567890)
Scientific Reports |         (2021) 11:7866  | https://doi.org/10.1038/s41598-021-86324-w
www.nature.com/scientificreports/
Atherosclerosis, a disease characterized by low-grade, chronic inflammation and accumulation of lipids in the 
arteries, is the main underlying cause of cardiovascular disease (CVD)1–3. The aetiology of atherosclerosis is 
still not completely understood but seems to involve a complex interplay of traditional CVD modifiable- and 
non-modifiable risk factors.
Among these traditional risk factors, diet and its content of fats may affect the development of  atherosclerosis4. 
A diet high in saturated fat including high intake of meat, dairy products and eggs, has been suggested to increase 
circulating atherogenic lipoproteins and inflammatory  markers5,6 and to trigger atherosclerotic development 
through endothelium dysfunction and plaque rupture  vulnerability5. Current European and American cardiovas-
cular guidelines recommend to reduce saturated fats and replace them with unsaturated  fats7,8, based on strong 
evidence from experimental  studies5. However, recent epidemiological studies have failed to show an increased 
risk of CVD in relation to a diet rich in saturated  fat9–14. Studies investigating the relation between saturated fat 
intake and surrogate measures of atherosclerosis, mainly carotid intima-media thickness (C-IMT), have shown 
inconsistent results indicating either increased C-IMT15–22 or no  associations23–27.
Several single nucleotide polymorphism (SNPs) related to subclinical or clinical atherosclerosis have been 
identified with genome-wide association studies (GWAS)28. These studies did not consider interaction effects. The 
findings have been confirmed by replication only  recently29. Estimates of heritability of carotid atherosclerosis 
vary between 20 and 75%28,30,31. As suggested from twin studies, the remaining heritability may be explained by 
interactions between the genetic susceptibility and lifestyle/environmental  factors28,32.
Studies investigating interactions between genes and dietary fats in relation to atherosclerosis are  scarce33–36, 
and focused exclusively on interactions between candidate genes and dietary n-6 and n-3 polyunsaturated fatty 
acids (PUFA) in relation to carotid  atherosclerosis33,35,36 or progression of coronary  atherosclerosis34. Interactions 
were found for most of the candidate genes under evaluation: arachidonate 5-lipoxygenase (ALOX5)33, leukot-
riene A4 hydrolase (LTA4H)35,36 and sterol regulatory element binding protein-1 (SREB1)34 but not for insulin-
induced gene-1 (INSIG1) and SREB cleavage-activating protein  (SCAP)34. To our knowledge, no previous study 
carried out a genome-wide-screening for genetic variants-dietary fat interactions in relation to atherosclerosis.
In a European multicenter study of men and women, we aimed to investigate the relationship between self-
reported intake of food rich in saturated fat and C-IMT. Based on the evidence from experimental  studies5, we 
hypothesized a positive relationship. Our aim was also to explore whether genetic predisposition may modulate 
this association.
Material and methods
The data that support the findings of this study are available from the corresponding author upon reasonable 
request.
Study population. The present study is based on data from the IMPROVE material, a multicenter longi-
tudinal study including 3,703 subjects (48% women), aged 54–79 with at least three CVD risk factors (male sex 
or at least 5 years after menopause for women, hypercholesterolemia, hypertriglyceridemia, hypoalphalipopro-
teinemia, hypertension, diabetes or impaired fasting glucose, smoking habits, or family history of cardiovascular 
diseases) but free of cardiovascular events at enrollment. Details of the study are reported  elsewhere37,38. In brief, 
between 2004 and 2005, study participants were recruited in seven centers across five European countries (two 
centers in Italy and Finland, one center in France, The Netherlands and Sweden). The main objective of the 
IMPROVE study was to investigate the associations between subclinical atherosclerosis, measured by C-IMT, 
and future CVD events. Subjects underwent a physical examination, which encompassed sonographic measure-
ments of C-IMT, at baseline and after 30 months. At baseline, they also completed a questionnaire concerning 
medical history, lifestyle and socioeconomic factors. In addition, blood samples were collected for biochemical 
testing and genotyping. The study was approved by the Institutional review board (IRB) at each recruitment 
centre (Karolinska Institutet, Stockholm, Sweden; University of Milan, Milan, Italy; University of Kuopio and 
Kuopio Research Institute of Exercise Medicine, Kuopio, Finland; University Hospital Groningen, Groningen, 
The Netherlands; University of Perugia, Perugia, Italy; Groupe Hôpital Pitie-Salpetriere, Paris, France). Written 
informed consents for general participation and for the genotyping were provided by all participants. The study 
was conducted in accordance with the Helsinki Declaration.
Assessment of dietary saturated fat. Participants were asked to recall their consumption, over the last 
12 months, of specific items including food rich in fats as follows: milk (ml/day and whether skimmed, semi-
skimmed or whole), meat, fish and eggs (times/week) and type of fat and oil usually consumed (lard, butter, olive 
oil, seed oil, margarine)37. From the dietary information collected, we created a binary variable to distinguish 
between high and low intake of food rich in saturated fat. Such binary exposure variable was required for our 
chosen method to assess interactions. Detailed description of how the binary dietary variable was formed is 
given in the Supplementary Materials, Section Materials and Methods. Briefly, it was formed based on a dietary 
score we created from a selection of the questions on diet in the questionnaire. We chose this approach over 
other approaches, such as using grams of saturated fat intake per day, because of the advantage of this approach 
in that it better takes into account the overall diet and therefore to some extent should take into account the 
complex interplay between nutrients. The binary dietary variable was roughly validated in a subsample of study 
participants (n = 523) for whom data on circulating serum fatty acids are available. Although in vivo fatty acids 
are inherently an imperfect reflection of dietary fat intake, in particular of saturated fat  intake39, such validation 
can give an idea of whether our principal exposure variable captures real intake. Details about the assessment 
of fatty acids in these individuals, who are simultaneously participants in the Cohort of 60-year-olds in Sweden, 
have been described  earlier40. Thirty-nine subjects had missing information on the dietary variable.
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Genotyping and quality control in IMPROVE. Illumina Cardiometabo 200   K41 and Immunochip 
200  K42 bead array platforms were used to genotype individual DNA extracted from blood samples. Quality con-
trol was performed on the individual chips followed by a further round on the combined chips. During quality 
control we excluded single nucleotide polymorphisms (SNPs) with low call rate, (< 95%), low minor frequency 
allele (< 0.05) and deviation from Hardy–Weinberg equilibrium (p < 1 ×  10–6). We also excluded participants 
with low call rates (< 95%), relatedness, discrepancy between sex chromosome and registered sex. Multi-dimen-
sional scaling was performed (using default settings in  PLINK43 to explore population stratification. Outliers 
were visually identified and excluded. Hence, 100,350 SNPs and 3,407 individuals were available for the gene-
diet interaction analysis.
Ultrasonographic measurements. B-mode ultrasound was performed to measure C-IMT at baseline 
and after 30  months. The protocol and the precision of the measurements have been described  elsewhere37. 
The mean and maximum of the average of the values measured in the left and right wall of the whole carotid 
tree (C-IMTmean and C-IMTmax) and in the specific segments including common carotid artert  (CCmean and 
 CCmax), bifurcations  (Bifmean and  Bifmax) and internal carotid artery  (ICAmean and  ICAmax) were available. Based 
on recommendation by The American Society of Echography (ASE) Task force, a binary variable with a cut-
point ≥ 75th percentile was created for each C-IMT baseline measurement to identify those subjects with abnor-
mal C-IMT44. To assess atherosclerotic progression, the measures at 30 months after the baseline were com-
pared to baseline results and change in C-IMT over time (mm/year) was  calculated38. A binary variable with a 
cut-point ≥ 75th percentile was created for each C-IMT progression measurement. Any positive change (above 
zero) was considered a cut-point to identify those who had progressed over the 30-month follow-up period. The 
reference category included those with no change or who instead had atherosclerotic regression. We excluded 
participants with missing information on C-IMT progression (n = 307) and those who had a CVD event over 
the follow-up (n = 193).
Statistical methods. For descriptive purpose, continuous variables were summarized as median and IQ 
range and categorical variables were presented as percentages.
For the validation of the dietary binary variable “high intake of food rich in saturated fat”, Spearman partial 
correlation analyses were employed to assess its correlations with circulating saturated fatty acids (C14:0, C15:0, 
C16:0 and C18:0), monounsaturated fatty acids (C16:1 and C18:1) and polyunsaturated fatty acids (n-6: C18:2, 
C18:3, and C20:4; n-3: C18:3, C20:4 and C20:5). Correlation coefficients (r) were considered significant for p 
values < 0.05.
Logistic regression models and 95% confidence intervals (CI) were employed to evaluate the associations 
between high dietary saturated fat intake and abnormal C-IMT at baseline and progression over 30-month 
follow-up. Models were adjusted for sex and age (Model 1) and levels of physical activity, education, alcohol 
consumption, smoking and MDS 1–3 (Model 2). In addition, sex-stratified analyses were performed.
Gene-diet interaction analysis in relation to abnormal C-IMT were computed using the GEIRA program 
designed to screen for genome-wide gene-environment  interactions45. Analyses were performed under the 
assumption of a dominant genetic model (one or two copies of the minor allele were combined to form the risk 
variant). Odds ratios (OR) with 95% CI of abnormal  CIMTmax at baseline were estimated for the following groups: 
1) double exposed (high intake of food rich in saturated fat while having risk variant), 2) exposed to high intake 
of food rich in saturated fat while not having the risk variant and 3) exposed to having the risk variant but not to 
high intake of food rich in saturated fat. The reference category was the group with neither of the two exposures. 
Adjustments were made for sex, age, physical activity, education, alcohol consumption, smoking and MDS 1–3. 
Among the C-IMT measures available, C-IMTmax was chosen, for reproducibility reason, since it is commonly 
used in other studies. Moreover, C-IMTmax has been shown to predict CVD events in this  population46. Interac-
tions were tested on the additive scale and thus defined as departure from additivity of  effects45,47. The aforemen-
tioned ORs were used to derive the Relative Excess Risk due to interaction (RERI)45. The 95% CI for this measure 
was computed using Hosmer and  Lemeshow48. P-values of < 5 ×  10–7 for RERI were considered significant after 
Bonferroni correction (0.05 alpha test/100,350 SNPs). We also tested for multiplicative interactions using the 
cross-product of each SNP and the dietary variable (p < 5 ×  10–7 after Bonferroni correction).
Analyses were performed using PLINK 1.7 (quality control analysis), SAS 9.4 (SAS institute, Cary NC, USA; 
gene-diet interaction analysis) and STATA 12.1 (Corp, College Station, TX, USA; remaining analysis) statistical 
software.
Results
Baseline characteristics among the 3,407 participants of the IMPROVE by their intake of food rich in saturated 
fats are presented in Table 1. High intake of food rich in saturated fats was more common among the participants 
recruited from the northern regions including Groningen, Stockholm and Kuopio. Compared to subjects with 
low intake of food rich in saturated fats, those with high intake were more likely be smokers, with low education, 
physically inactive, hypertensive and diabetic. They also had higher mean values of BMI and CRP but were less 
likely to have hypercholesterolemia (Table 1). Baseline characteristics differed between men and women: men 
were more likely to have high intake of food rich in saturated fat and to have diabetes whereas women were 
more likely to have hypercholesterolemia and hypertension. Further, men consumed more alcohol than women, 
whereas women were less physically active and had a lower level of education than men. (Suppl Material, Table 1).
Results from the validation analyses showed significant positive correlations between self-reported high 
intake of food rich in saturated fat and serum concentration of the saturated stearic acid, C18:0 (r 0.13) and the 
n-6 polyunsaturated fatty acid linoleic acid (r 0.09), whereas significant inverse correlations were observed with 
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total n-3 polyunsaturated fatty acids (r -0.23) including C20:5 (r -0.20) and C22:6 (r -0.25). No other significant 
correlation was observed.
Associations between intake of food rich in saturated fat and abnormal baseline C-IMT are shown in Table 2. 
Sex- and age- adjusted odds of abnormal C-IMTmean, CC-IMT mean and ICA-IMTmean were higher in the group 
with high intake of food rich in saturated fat as compared to those with low intake. However, after adjustment 
for lifestyle factors, education and MDS 1–3, results were no longer significant.
No associations between intake of food rich in saturated fat and C-IMT progression were observed either in 
Model 1 or 2 (Table 3).
Results from the sex-stratified analyses of the association between intake of food rich in saturated fat and 
C-IMT, baseline and progression, also did not show any clear associations (data not shown).
Results from the gene-dietary fat interaction analyses are shown in Suppl Material Table 2. Before Bonferroni 
adjustment, a statistically significant (P-value < 0.05) RERI value was observed for 1,450 of the SNPs tested for 
interaction with high intake of saturated fat (Suppl Material Table 2). Of those results, 1,449 indicated antagonism 
and one indicated synergism. After Bonferroni correction, none of these results remained statistically significant 
(P value for RERI < 0.05 ×  10–5).
Table 1.  Baseline characteristics of the participants included in the IMPROVE study by intake of food rich 
in saturated fats. *median and IQ range. **p values were calculated with Pearson’s chi-squared test for discrete 
variables and Wilcoxon rank-sum test for continuous variables. S: serum. m: missing.
Variables
Low intake of food rich in saturated 
fats
High intake of food rich in saturated 
fats p value**
All (n) 1,712 1,695
Women(%) 55 48 0.000
Age (y)* 64.3 (59.7;67.2) 64.8 (59.7;67.2) 0.69
Recruitment center(%; n) 0.000
Southern regions
 Perugia 15; 254 15; 246
 Milan 23; 391 8; 136
Parism11 18; 308 9; 145
Northern regions
  Groningenm27 4; 64 23; 386
 Stockholm 13; 229 18; 299
  Kuopiom1 27; 466 29; 483




Ever  smoker(%) 12 17 0.000
Education(%) m43 0.000
 ≤ 9 y 44 48
9–12 y 23 28
 > 12 y 33 24
Alcohol consumption(%) m19 0.163
0 g/day 47 44
 > 0– ≤ 10 g/day 16 17
 > 10–30 g/day 20 23
 > 30 g/day 17 17
Hypertension(%) 69 75 0.000
Hypercholesterolemia(%) m4 80 60 0.000
S-Total cholesterol (mmol/L)m16* 5.5 (4.8;6.3) 5.4 (4.6;6.2) 0.005
S-High-Density Lipoprotein (mmol/
L)m16* 1.23 (1.04;1.50) 1.18 (0.98;1.44) 0.000
S-Low-Density Lipoprotein (mmol/L)m80a 3.54 (2.90;4.29) 3.46 (2.76;4.16) 0.003
S-Triglycerides (mmol/L)m16* 1.28 (0.92;1.83) 1.35 (0.95;1.97) 0.001
Diabetes(%)m63 20 30 0.000
S-Glucose (mmol/L)m12* 5.4 (4.9;6.1) 5.6 (5.0;6.6) 0.000
S-C-Reactive Protein (mmol/L)m11* 1.64 (0.67;3.36) 2.09 (0.92;3.89) 0.000
Body Mass Index (Kg/m2)m3* 26.4 (23.8;28.8) 27.3 (24.8;30.0) 0.000
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Discussion
In this European population at high risk of CVD but free of clinical manifestations of CVD, no significant asso-
ciations were found between a diet rich in saturated fat and abnormal C-IMT, nor progression of C-IMT, after 
adjustments for sex, age, level of education and lifestyle factors. Moreover, we found no significant evidence 
of interactions between high intake of saturated fat and genetic variants in relation to carotid atherosclerosis.
Dietary saturated fat in relation to baseline C-IMT and C-IMT progression. Our result of no asso-
ciation between a diet rich in saturated fat and abnormal baseline C-IMT is in line with results of some previ-
ous epidemiological  studies23–25,27. These studies were relatively small (n < 1100) and performed in Australian 
 women23, Finnish  men24,25 or Spanish men and  women27. However, our result does not support findings of 
other previous studies, performed in  Canada16, the U.S.17,19,22 and  Korea15,20 showing associations with increased 
atherosclerosis. In general, in most of the previous studies, the exposure assessment was limited to the intake of 
specific food items rich in saturated fat—dairy products, meat or  eggs15,19,20,22–25,27—which may not capture the 
overall intake of saturated fats. However, in the  Canadian16 and U.S.17 studies, the total intake of saturated fat (g/
day) in relation to C-IMT was considered. The U.S. study was performed between 1987 and 1989 and included 
7,100 women and 5,900 men from the general population, with a mean age of 54; the association with increased 
C-IMT was found in women  only17. In the Canadian study, participants (n = 620), aged 55 on average, were with-
out CVD risk factors and the association with increased C-IMT was  modest16. Interestingly, the studies which 
agree with our results were mainly performed in Europe, whereas those with opposite results were performed 
in non-European countries. The discrepancy between our results and those reported from non-European popu-
lations may perhaps be explained by different dietary patterns, methods of cooking, source of dietary fat or 
total amount consumed daily. Micha et al.49 showed that the amount and sources of saturated fats may vary by 
geographical regions with Western European countries consuming less processed meat but more vegetables and 
whole grain than Northern American  countries49. In light of our results, it is also noteworthy to consider that 
our study population has been shown to have a good compliance to a Mediterranean diet in general, although 
with a north–south  gradient50, in which the fundamental components such as whole grain and alcohol have been 
shown to modify the increased risk of CVD associated with high intake of dietary saturated  fat51.
Table 2.  Odd Ratios (OR) and 95% confidence interval (CI) of abnormal C-IMT for high consumption of 
food rich in saturated fat (vs. low) in the participants of the IMPROVE study. m: missing. Model 1: Sex- and 
age-adjusted. Model 2: Model 1 plus level of education (categorical), physical activity (categorical), smoking, 
alcohol consumption (categorical) and population structure (MDS1-3, continuous).
OR (95% CI) OR (95% CI)
Model 1
 (n = 3,407)
Model 2
 (n = 3,364)
IMTmeanm2
<75th percentile Ref Ref
 ≥ 75th percentile 1.25 (1.06;1.47) 1.15 (0.97;1.37)
IMTmaxm2
<75th percentile Ref Ref
 ≥ 75th percentile 1.17 (1.00;1.37) 1.12 (0.95;1.32)
CC–IMTmeanm3
<75th percentile Ref Ref
 ≥ 75th percentile 1.22 (1.04;1.44) 1.17 (0.98;1.38)
Bif–IMTmeanm21
<75th percentile Ref Ref
 ≥ 75th percentile 1.04 (0.89;1.22) 1.03 (0.88;1.22)
ICA IMTmeanm32
<75th percentile Ref Ref
 ≥ 75th percentile 1.26 (1.07;1.48) 1.18 (1.00;1.40)
CC–IMTmaxm3
<75th percentile Ref Ref
 ≥ 75th percentile 0.97 (0.83;1.14) 0.94 (0.80;1.11)
Bif–IMTmaxm21
<75th percentile Ref Ref
 ≥ 75th percentile 1.10 (0.95;1.29) 1.12 (0.95;1.31)
ICA–IMTmaxm32
<75th percentile Ref Ref
 ≥ 75th percentile 1.10 (0.94;1.29) 1.02 (0.86;1.20)
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Our finding of no association between dietary saturated fat and C-IMT progression confirms the results 
reported from two interventional studies (n < 300), performed in Dutch men and  women18 and Norwegian 
elderly  men26. Similar to our study, these two investigations were carried out in participants with risk factors 
for CVD over an average of 30 months follow-up for  atherosclerosis18,26. Considering the limited knowledge 
concerning the relationship between intake of saturated fat and C-IMT progression, further studies are needed 
to confirm this null association.
Our findings of no association between intake of saturated fats and carotid atherosclerosis do not agree with 
the previously suggested detrimental effects from saturated fats on cardio-metabolic risk markers and patho-
physiologic pathways involved in the atherosclerotic  process5. However, recent results from the Prospective 
Urban Rural Epidemiology (PURE) study showed that replacement of saturated fatty acids with carbohydrate 
or polyunsaturated fat may have a detrimental effect on blood lipids such as triglycerides and High-Density-
lipoprotein (HDL)52. In addition, in the PURE study a steep reduction in the intake of saturated fat resulted in 
only a moderate change of Low-Density-lipoprotein (LDL)52. Moreover, in the Dietary Intervention and Vascular 
Study, the replacement of saturated fatty acids with PUFA had no effect on vascular  function53.
Absence of findings of gene-dietary saturated fat interactions. To the best of our knowledge, no 
previous studies have investigated interactions between genetic variation and dietary fats in relation to abnormal 
C-IMT using a non-hypothesis driven approach based on genetic data from genome-wide screening. Opposite 
to what perhaps may be expected, our results suggest that single genetic variants do not influence the impact 
of dietary saturated fats on atherosclerosis. A potential explanation of our null findings might however be that 
effects are not large enough to be detectable in our sample. Thus, the possibility of false negative results in our 
study should be noted.
Limitations. The main limitation of the present study is the basis for assessment of dietary fat intake. Con-
sidering that a simple short self-reported questionnaire was used, misclassification of the saturated fat intake 
may have occurred. However, the results from our validity analyses lend some support to the assumption that the 
self-reported intake of saturated fat reflects the actual intake. Of course, it is still possible that such misclassifica-
Table 3.  Odd Ratios (OR) and 95% confidence interval (CI) for high consumption of food rich in saturated 
fats in relation to IMT progression (vs. no change or regression) in the participants of the IMPROVE study. 
Participants with missing information on progression (n = 307) and those who suffered a cardiovascular event 
during the follow-up (n = 193) are excluded. Model 1: Sex- and age-adjusted. Model 2: Model 1 plus level 
of education (categorical), physical activity (categorical), smoking, alcohol consumption (categorical) and 
population structure (MDS1-3 continuous).
OR (95% CI) OR (95% CI)
Model 1
 (n = 2,907)
Model 2
 (n = 2,864)
IMTmean
No change or regression Ref Ref
Progression 1.10 (0.93;1.30) 1.14 (0.95;1.35)
IMTmax
No change or regression Ref Ref
Progression 1.03 (0.88;1.20) 1.06 (0.90;1.24)
CC–IMTmean
No change or regression Ref Ref
progression 0.86 (0.74;1.00) 0.87 (0.75;1.02)
Bif–IMTmean
No change or regression Ref Ref
Progression 1.11 (0.95;1.30) 1.13 (0.96;1.34)
ICA IMTmean
No change or regression Ref Ref
Progression 1.06 (0.90;1.23) 1.06 (0.90;1.24)
CC–IMTmax
No change or regression Ref Ref
Progression 0.93 (0.80;1.08) 0.95 (0.82;1.11)
Bif–IMTmax
No change or regression Ref Ref
Progression 1.01 (0.86;1.17) 1.02 (0.87;1.20)
ICA–IMTmax
No change or regression Ref Ref
Progression 1.08 (0.93;1.25) 1.05 (0.90;1.22)
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tion has occurred to some extent, but it is likely to be non-differential and may have biased the results towards 
the null. Beyond the potential misreporting, misclassification may also be induced by our analytic method, in 
which we created a binary variable reflecting intake of saturated fats, possibly oversimplifying the underlying 
dietary intake of fat. Our assessment of dietary fat intake encompassed no characterization of the saturated fat 
which is another limitation. Not all saturated fatty acids have been shown to have the same effect on lipoproteins 
involved in the atherosclerotic  process54. Hence, in further studies, it would be important to consider dietary 
saturated fat with a specific focus on the different type of saturated fats in relation to subclinical atherosclerosis.
The presence of unmeasured confounding in this study cannot be ruled out. For instance, adjustment for 
carbohydrate intake was not possible due to the lack of this information in the dietary questionnaire which 
mainly captures fat intake, especially saturated fat.
This study was performed in participants with at least 3 traditional CVD risk factors which limits the gener-
alizability of results to the general population. Further, the generalizability may be hampered by heterogeneity 
among participants in terms of intake of food rich in saturated fats and adherence to a Mediterranean diet. 
Moreover, study participants may have changed their diet upon being diagnosed with a metabolic condition 
such as hypertension, hyperlipidemia or diabetes, causing a possible decrease in their intake of saturated fats 
and thus a saturated fats intake classification in our study that does not reflect a long-term dietary habit. The 
heterogeneity of our study population may also have hampered the possibility to detect significant interactions; 
hence our absence of findings should be interpreted with caution.
Finally, it should be noted that C-IMT may be questioned regarding its role as a surrogate marker for subclini-
cal atherosclerosis: it may reflect a combination of vascular aging and the atherosclerotic  process55,56. However, 
among the available surrogate markers of subclinical atherosclerosis, C-IMT is one of the most widely used and 
 recognized57–61. Further, the uncertainty surrounding the C-IMT measure should be weighed against the benefit 
obtained, from a pathophysiological research perspective, of studying subclinical atherosclerosis instead of mani-
fest CVD, as the latter outcome may have a larger width of underlying pathophysiological causal mechanisms.
Conclusions
In this European population with at least three risk factors for CVD but free of CVD at baseline, a diet rich in in 
saturated fat was not associated with atherosclerosis nor its progression measured after 30 months. Our results 
suggest that the relationship between a diet rich in saturated fat and subclinical atherosclerosis is not modulated 
by specific genetic variants. These findings need to be confirmed in further studies.
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